Only supervised low-dose tirzepatide or semaglutide plans may help some patients, depending on their tolerance, wellness goals, and maintenance needs
March 13, 2024
Who shouldnt use these peptides: Anyone with active cancer or a recent cancer history (GH and IGF-1 can stimulate growth of some malignancies) Severe uncontrolled diabetes, GH worsens insulin resistance Active proliferative diabetic retinopathy Pregnancy or breastfeeding Children or adolescents (growth plates still open) FDA 503A and what changed for sermorelin compounding This is the part of the conversation most clinic-marketing pages avoid, and it matters enough that you should know it before you start.In late 2023, the FDA reclassified sermorelins bulk substance status, removing it from the 503A compounding pathway that traditional compounding pharmacies operate under
Mousavi A, Shojaei S, Soleimani H, Semirani-Nezhad D, Ebrahimi P, Zafari A, et al
Some people may feel a slight discomfort when the needle is inserted in the vein, or may experience bruising, itching, inflammation or redness at or around the infusion site, which disappears after a few minutes or several days
%25201.png)
